Related Experiment Videos
Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas
Klaus Urbahns1, Michael Härter, Andrea Vaupel
1Institute of Medicinal Chemistry, Pharma Research Center, Bayer AG, D-42096 Wuppertal, Germany. klaus.urbahns.ku1@bayer.co.jp
Bioorganic & Medicinal Chemistry Letters
|March 20, 2003
Abstract:
Vitronectin receptor (alpha(V)beta(3)) antagonism has been implicated in a variety of disease states, like restenosis, osteoporosis and cancer. In this work, we present the development of a novel class of biphenyl vitronectin receptor antagonists. Identified from a focused combinatorial library based on para-bromo phenylalanine, these compounds show nanomolar affinity to the vitronectin receptor and display unprecedented SAR. Their binding mode can be rationalized by computational docking studies using the X-ray structure of alpha(V)beta(3).